Depression and Antidepressants in Pregnancy: What a Large Welsh Study Found About Children's Learning Needs

Depression during pregnancy is common, and so is the question of whether treating it with medication carries any risk for a child's later development. A new study published in PLOS Medicine, drawing on health and education records for more than 167,000 children born in Wales, adds detailed data to this long-running debate without settling it entirely.

What the researchers looked at

The team linked maternity records, GP prescribing data, and school records to follow children from birth up to an average age of nearly six. They grouped mothers into several categories: those with a depression diagnosis but no antidepressant prescription, those with both a diagnosis and a prescription, and those who received an antidepressant without a recorded depression diagnosis in their health records. The main outcome was whether a child had been identified as having a special educational need (SEN), a broad category covering things like autism spectrum diagnoses, communication difficulties, learning difficulties, and behavioral or emotional challenges. The researchers also looked separately at ADHD diagnoses over time.

The main patterns in the data

Children whose mothers had depression during pregnancy, whether or not it was treated, had a higher likelihood of having a recorded special educational need than children whose mothers had no depression history. Roughly 20 out of every 100 unexposed children had an SEN, compared with about 23 to 24 per 100 among children whose mothers had untreated depression. The number rose further, to roughly 26 per 100, among children exposed to antidepressants, regardless of whether their mothers also had a documented depression diagnosis.

Statistically, both depression exposure and antidepressant exposure were linked to higher odds of SEN after the researchers adjusted for factors such as deprivation, maternal age, smoking, and other pregnancy-related variables. Associations also appeared for specific categories, including autism spectrum diagnoses and ADHD, with antidepressant exposure showing a somewhat stronger statistical link than depression alone in these subgroups. When the researchers compared different types of antidepressants, no single class stood out as clearly safer or riskier overall, though tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors showed some differences worth further study.

Why disentangling cause is so difficult

Studies have found that women who are prescribed antidepressants during pregnancy tend to have more severe or persistent depression than those who go untreated. That means any extra risk linked to medication use could, at least partly, reflect the underlying severity of the illness rather than an effect of the drug itself. This is known as confounding by indication, and it has limited many previous studies on this topic too.

The study's design, built on health records rather than a controlled trial, means it can identify associations but cannot prove that antidepressants directly cause neurodevelopmental differences. The researchers describe the added risk tied to medication as modest in absolute terms, even though the statistical associations were clear. For context, the gap between the highest-risk group (depression plus medication) and the lowest-risk group (no exposure to either) worked out to roughly six to seven extra cases of SEN per 100 children.

One of the more striking details in the paper is that children exposed to untreated depression also showed meaningfully higher rates of SEN compared to unexposed children. This suggests that maternal depression itself, independent of any treatment decision, is associated with child neurodevelopmental outcomes. The researchers conclude that the increased risk seen in children exposed to antidepressants cannot be explained by medication alone, and likely reflects a mix of depression severity and other unmeasured factors — a question they say future research will need to untangle further.

Pregnant women managing depression face a genuinely difficult balance: untreated depression carries its own risks for both mother and child, and antidepressant use shows a small additional statistical association with neurodevelopmental outcomes that current data can't fully explain. Decisions about starting, continuing, or stopping antidepressant treatment during pregnancy are personal and medical in nature, best worked through with a doctor or psychiatrist rather than decided from population-level findings alone.

Source: PLOS Medicine, DOI: 10.1371/journal.pmed.1004658 — findings reported by McIlvride et al. based on a population cohort study of children born in Wales, UK.